Background and Purpose-The association of neutrophil and intracranial artery stenosis (ICAS) with the prognosis of stroke is uncertain. This study evaluated the relationship between neutrophil levels with and without ICAS and the prognosis of patients with minor stroke or transient ischemic attack. 
D
espite aggressive medical treatment, certain proportion of patients with minor stroke or high-risk transient ischemic attack (TIA) still developed recurrent stroke. 1, 2 Previous studies have shown that intracranial artery stenosis (ICAS) is an independent predictor for stroke recurrence, even in patients already on dual-antiplatelet therapy. [3] [4] [5] [6] Therefore, it is likely that other conditions, such as immune/inflammation response, after stroke might play a role in stroke recurrence. Neutrophils-indicators of acute and chronic inflammationare the first cells to migrate from the peripheral vessel into the brain ischemic zone after cerebral infarctions. 7 The increased number of neutrophils accelerates inflammatory process by releasing cytotoxins, in which the ischemia insult is intricately aggravated. 8 In our investigation, elevated neutrophil counts were associated with the recurrence of stroke in patients who already had a minor ischemic stroke or high-risk TIA. 9 Neutrophils not only have a pivotal role in the development of ICAS but also are an independent predictor of mortality in patients with asymptomatic carotid stenosis 10 and poor cardiovascular outcome in patients with symptomatic peripheral artery disease. 11 However, the outcome related to the interaction or combined effect of elevated neutrophils with and without ICAS in patients with symptomatic cerebrovascular disease is uncertain.
Utilizing the data from the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), we assessed the association between neutrophil counts with and without ICAS and the predictability of recurrent stroke in patients who already had a minor ischemic stroke or TIA.
Methods

Study Design
Data from the CHANCE trial were reviewed. Details on the rationale, design, and major results of the CHANCE trial have been published previously. 1, 12 Briefly, CHANCE was a multicenter, randomized, double-blind controlled trial conducted at 114 hospitals in China from 2009 to 2012, in which 5170 patients within 24 hours after onset of a minor stroke or modest to high-risk TIA were randomized to the clopidogrel plus aspirin group or aspirin-alone group. The primary outcome of CHANCE was to assess the efficacy of clopidogrel plus aspirin in reducing stroke risk within 90 days in patients with high-risk TIA or minor stroke. The eligible patients in this trial met the following criteria: age, ≥40 years, a diagnosis of an acute minor ischemic stroke (National Institutes of Health Stroke Scale, ≤3) or high-risk TIA (ABCD2 [age, blood pressure, clinical features, duration of TIA, and presence or absence of diabetes score], ≥4), and able to initiate the study drug within 24 hours after onset. Data are available to researchers on request for reproducing the results or replicating the procedures by contacting the corresponding author.
Standard Protocol Approvals, Registrations, and Patient Consents
The protocol and data collection of the CHANCE trial were approved by the Ethics Committee of Beijing Tiantan Hospital and all other study centers. The informed consents were signed by all participants or their representatives before participating in the trial. The trial was registered at http://www.clinicaltrials.gov, and the registration number is NCT00979589.
Data Collection
Baseline data included demographics, clinical features, and vascular risk factors. Clinical features included body mass index, symptom onset to randomization, index event, and baseline National Institutes of Health Stroke Scale score. Vascular risk factors, such as the history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, valvular heart disease, diabetes mellitus, hyperlipidemia, and smoking, were also collected.
Whole-blood samples were collected in EDTA anticoagulated tube from patients within the first 24 hours after randomization at 114 study centers. Total neutrophil counts were tested using automated particle counters at the local hematology laboratory according to the local standard process. Patients were categorized into 4 groups according to the dichotomy of neutrophil levels (median, 4.3×10 9 per L) and status of ICAS 10 : lower neutrophil level (<4.3×10 9 per L) without ICAS, higher neutrophil level (≥4.3×10 9 per L) without ICAS, lower neutrophil level with ICAS, and higher neutrophil level with ICAS.
Imaging Collection and Analysis
The baseline magnetic resonance imaging (MRI) was required per protocol at 45 subcenters. The sequence of MRI included T1-weighted imaging, T2-weighted imaging, diffusion-weighted imaging, and 3-dimensional time-of-flight magnetic resonance (MR) angiography. Those without any of the aforementioned sequences of MR examinations at baseline were excluded from our study. All MRI were collected from participating sites in digital format and read centrally by 2 readers (X.Z. and J.J.), who were blinded to each other and clinical information of patients. Disagreement in the degree of stenosis of >10% was resolved by a third reader (Xia Meng).
The presence of ICAS was defined as 50% to 99% stenosis according to the WASID trial (Warfarin-Aspirin Symptomatic Intracranial Disease) criteria 13 or occlusion of at least 1 of the following arterial segments on maximum-intensity projections of 3-dimensional timeof-flight MR angiography: intracranial segment of internal carotid arteries, middle cerebral arteries (M1/M2), intracranial segment of vertebral arteries, and basilar artery. Patients with ICAS were further categorized into those with 1 or multiple arterial stenotic segments according to the number of ICAS lesions.
Outcome Assessment
The primary outcome was a new stroke onset during the 90-day follow-up. Secondary outcomes included a new composite vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, and death from cardiovascular cause) and ischemic stroke. Safety outcome was any bleeding event during the 90-day visit. The criteria for stroke, composite vascular event, ischemic stroke, and hemorrhage were in consistence with previously published outcomes of the CHANCE trial. 
Statistical Analysis
The baseline variables were compared between groups by using the χ 2 test or Fisher exact test for categorical variables and 1-way ANOVA or Kruskal-Wallis test for continuous variables with normal or skewed distribution, respectively. Continuous variables were expressed as means with SD or medians with interquartile range, as appropriate. Categorical data were presented as proportions.
To examine the interaction effect of neutrophil counts and ICAS status, we tested the statistical significance of neutrophil counts×ICAS presence or absence in a multivariable Cox model. Time to the primary efficacy outcome for each group was shown in a Kaplan-Meier curve and compared by the log-rank test. The associations between neutrophil counts with and without ICAS and prognosis of minor stroke or TIA were further assessed by using multivariable Cox regression models. Adjusted hazard ratios and their 95% CIs were calculated. Two models are used. In the first model, we adjusted only age and sex. In the second model, we included all the potential confounding variables.
Two-sided P values of 0.05 were considered statistically significant. All analyses were performed with SAS software, version 9.4 (SAS Institute, Inc, Cary, NC).
Results
Participants Recruited
In the CHANCE trial, 5170 patients were enrolled. Among them, 1089 patients had the eligible MRI sequence, and 4854 had the eligible neutrophil counts at baseline. Finally, a total of 1034 patients were retrieved in this subgroup analysis. Among these included patients, 457 had at least 1 ICAS of any intracranial artery, whereas the other 577 had no ICAS. Patients were divided into 4 groups as mentioned above: 308 (29.8%) had lower neutrophil levels but without ICAS, whereas 269 (26%), 196 (19.0%), and 261 (25.2%) had higher neutrophil levels without ICAS, lower neutrophil levels with ICAS, and higher neutrophil levels with ICAS, respectively.
Baseline characteristics of the included patients are shown in Table 1 . The average age of these subgroup patients was 63.2±10.7 years, and 358 (34.6%) patients were women. Patients with both higher neutrophil levels and ICAS were more likely to have a history of diabetes mellitus, an index event of minor stroke, and higher severity of stroke. Patients with lower neutrophil levels and ICAS were more likely to be elderly and have a history of ischemic stroke.
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Association of Neutrophil Counts, Pattern of ICAS, and the Outcome
During the 90-day follow-up, 91 (8.8%) patients had recurrent stroke, and all were new ischemic stroke. Meanwhile, 93 (9.0%) patients had composite events, whereas 21 (2%) had bleeding events. The levels of neutrophil with and without ICAS and associated risk of adverse outcome are shown in Table 2 . Patients with either higher neutrophil levels or ICAS had increased risk of recurrent stroke and composite events at 90 days, compared with the reference of those with lower neutrophil levels but without ICAS. After adjustment for model 1 (age and sex) and further adjustment for model 2 (body mass index, history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, atrial fibrillation or flutter, valvular heart disease, diabetes mellitus, hypertension, hyperlipidemia, smoking, time to randomization, index event, National Institutes of Health Stroke Scale on admission, and antiplatelet therapy), only patients who concomitantly present with both higher neutrophil levels and ICAS were associated with the worse outcome. The risk of stroke recurrence in this group was increased as high as 2.26-folds (95% CI, 1.19-4.31; P=0.01), whereas the risk of composite events was 1.98 (95% CI, 1.06-3.67; P=0.03). A combined but not interactive effect of the neutrophil levels with or without ICAS on the primary outcome was observed (P for interaction was 0.98 in the multivariable adjusted model).
Further analyses according to 1 or multiple ICAS segments showed a gradient association between numbers of ICAS segments and the risk of new stroke (P for trend, <0.001). Compared with those with lower neutrophil level and without ICAS, patients with multiple ICAS segments and lower (hazard ratio, 2.33; 95% CI, 1.00-5.41) or higher (hazard ratio, 2.65; 95% CI, 1.28-5.48) neutrophil level were associated with an increased risk of new stroke (Table 3) . Cumulative hazard of new stroke is shown in the Figure (logrank P, 0.001).
There was no safety concern between the levels of neutrophil with or without ICAS (P=0.56). After further adjustment for the confounding factors in model 1 and model 2, the findings were still similar in any of the group as comparing with the reference group.
Discussion
In this subgroup analysis of CHANCE trial, we found that patients with both higher neutrophil levels and ICAS were associated with an increased risk of recurrent ischemic stroke and composite events at 90 days. Gradient association was observed when further stratified by 1 or multiple ICAS. Higher neutrophil level with multiple ICAS was associated with 2.65-fold increased risk for new stroke. This overlaying effect was stronger to predict the risk of a new stroke than those with either elevated neutrophil counts or ICAS alone.
Patients with acute minor stroke or TIA were at high risk of having recurrent ischemic vascular events, especially if ICAS was also present.
14 Traditional statistical models based on clinical risk factors could not predict the entire events. 15 Thus, serum biomarkers involved in the pathophysiological process of vascular occlusive events may improve this BMI indicates body mass index; HR, hazard ratio; ICAS, intracranial artery stenosis; NIH, National Institutes of Health; and TIA, transient ischemic attack. *Model 1: adjusted for age and sex. †Model 2: adjusted for age, sex, BMI, history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, hypertension, diabetes mellitus, hypercholesterolemia, smoking status, index event and NIH Stroke Scale on admission, time to randomization, and antiplatelet therapy.
‡Composite events: stroke, myocardial infarction, or death from cardiovascular cause. BMI indicates body mass index; HR, hazard ratio; ICAS, intracranial artery stenosis; NIH, National Institutes of Health; and TIA, transient ischemic attack.
*Adjusted for age, sex, BMI, history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, hypertension, diabetes mellitus, hypercholesterolemia, smoking status, index event and NIH Stroke Scale on admission, time to randomization, and antiplatelet therapy.
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prediction. More and more experimental and clinical evidence showed that inflammation-a classical molecular mechanism-played a primary role in the occurrence of vascular events and worsening of outcome. Neutrophils, as major determinants of inflammation and the overwhelming components of leukocyte, have become the focus on the prediction for the adverse outcome in patients with vascular disease. Maestrini et al 16 found that higher neutrophil counts before the administration of tPA were associated with symptomatic intracranial hemorrhage and worse outcome in ischemic patients within window time. Shi et al 17 demonstrated that neutrophil elevation after tPA administration was associated with poor functional outcome.
In addition, neutrophils contribute to the development and progression of atherosclerosis as well. 18, 19 Increased neutrophils were linked to destabilization of carotid plaque. 20 Even in healthy population, the baseline neutrophil/lymphocyte ratio correlated with the burden of developing ICAS. 21 An association between higher neutrophil/lymphocyte and the severity of coronary artery stenosis has already been established. 22 Because ICAS is an independent risk factor for recurrent stroke and particularly highly prevalent in Asian population, 3, 14, 23 the existence of both ICAS and higher neutrophil counts may have the summation effect on predicting a worse outcome for patients with stroke. 18, 19 Our study confirmed the hypothesis that higher neutrophil levels with the presence of ICAS, especially multiple ICAS, were strongly associated with the increased risk of recurrent stroke and composite events in patients with minor stroke or high-risk TIA. Interestingly, if a patient has lower neutrophil levels (cutoff value at 4.3×10 9 per L) with 1 ICAS segment or higher neutrophil level without ICAS, this association was not present-a phenomenon that would need further study. Nasr et al 24 demonstrated that baseline neutrophil counts were associated with cerebral microembolization in patients with symptomatic carotid stenosis. Therefore, we speculated that ICAS with higher neutrophil levels might represent unstable plaque or a diseased vessel responsible for the index ischemic event.
Although the underlying mechanism of correlating neutrophils with the worse outcome remains uncertain, more experimental stroke models and human MRI researches have revealed that neutrophils may have played a pivotal and initiating role in the early stage of stroke. 8, 25, 26 As the first inflammatory cells recruited into the ischemic zone, neutrophils initiated the migration of subsequent inflammatory/immune cells by releasing detrimental molecules, such as reactive oxygen species and proinflammatory mediators, 27, 28 which may aggravate infarct growth and cause symptom deterioration. In addition, neutrophils promote thrombosis through a variety of pathways, including the release of molecules responsible for neutrophil extracellular trap formation and protease cathepsin G, as well as direct interactions with platelets. 28 A previous study showed that the interaction of neutrophils and platelets was enhanced in those with symptomatic carotid stenosis. 29 Therefore, the proinflammatory and prothrombotic function with neutrophils contributes to the cause of recurrent occlusive arterial events.
In this study, the combination of imaging features and biomarker was a strong indicator for stroke recurrence, exceeding the predictability of using any 1 of the individual markers alone. The significance of this study is that predicting the prognosis should include the findings of pathophysiological mechanisms in addition to clinical risk factors.
Limitations of the Study
Although this post hoc analysis was based on the data from a large, multicenter, double-blinded, and high-risk patientsbased design trial, there were still several limitations. First, heterogeneity of cell autoanalyzed instrument at 114 centers could lead to biased estimates of association, but this effect was minimized because of strict quality control in every center. Second, the measurement of neutrophil counts was recorded only once at baseline. Because neutrophil counts are a dynamic process and change moment to moment during the progression of stroke, the dynamic fluctuation of neutrophil might be more meaningful. 17 Third, responsible arterial stenosis or occlusion was not defined in this study. It was difficult to define responsible arterial stenosis or occlusion because a considerable percentage of patients had TIA as the index event or had multiple infarcts. Fourth, only MR angiography was used to estimate the stenosis. MR angiography has limited spatial resolution and may not be sensitive to offer accurate assessment of arterial stenosis as compared with catheter angiography. Fifth, the generalizability of the results of this subgroup analysis need further validation because of higher prevalence of ICAS in Asian descent than those of Western descent. 23, 30 Finally, residual bias might still exist because neutrophil counts could also be affected by comorbidities, such as tumor, trauma, and uncertain inflammation. More studies would be needed to verify our findings.
Conclusions
Increased neutrophil counts with the presence of ICAS were strongly associated with the incidence of recurrent stroke, composite end points in patients with an acute minor stroke, or high-risk TIA at 90-day follow-up. 
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